Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SOD1 | P00441 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627950 | 0.90 | QPCT (0.54) | QPCTMAPTNAMPTKDM4EGAA | |
| SCHEMBL3629884 | 0.89 | NAMPT (0.56) | LMNARAB9AQPCTMAPTNAMPT | |
| SCHEMBL3630435 | 0.88 | NAMPT (0.51) | LMNARAB9AQPCTMAPTNAMPT | |
| SCHEMBL3629417 | 0.87 | TP53 (0.60) | LMNARAB9AQPCTMAPTKDM4E | |
| SCHEMBL3632275 | 0.85 | SMN1; SMN2 (0.53) | LMNARAB9AQPCTMAPTNAMPT | |
| SCHEMBL3631542 | 0.84 | KDM4E (0.49) | LMNARAB9AQPCTMAPTKDM4E | |
| SCHEMBL3626572 | 0.84 | ALDH1A1 (0.51) | LMNARAB9AQPCTMAPTKDM4E | |
| SCHEMBL3629866 | 0.83 | ALDH1A1 (0.53) | LMNARAB9AQPCTMAPTNAMPT | |
| SCHEMBL3631942 | 0.83 | QPCT (0.52) | QPCTKDM4EGAAALDH1A1 | |
| SCHEMBL3632102 | 0.82 | QPCT (0.56) | QPCTMAPTNAMPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142536-B1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-10-21 | — | — | EP | claimed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | claimed |
| EP-2142536-B1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2142536-B1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| EP-2142536-A1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008128984-A1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128984-A1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | LMNA 2928/4885RAB9A 514/4885QPCT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.